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and collagen normally provide the resilience and tensile
strength needed for the aorta to withstand hemodynamic
stress, destruction of the elastic media is an early event in
aneurysmal degeneration, and collagen degradation is con-
sidered necessary for aneurysm expansion and rupture.2
Human and experimental AAAs are also associated with
chronic transmural inflammation and elevated local expres-
sion of enzymes that mediate matrix protein degradation,
including matrix metalloproteinases (MMPs), plasminogen
activators, and cathepsins.3-7 Pharmacologic strategies
aimed at preventing matrix degradation may therefore have
promise in the management of small asymptomatic AAAs.8
Angiotensin-converting enzyme (ACE) inhibitors are
widely used in the treatment of hypertension, congestive
heart failure, and other cardiovascular disorders.9,10 In
addition to their antihypertensive effects, these compounds
are recognized as having a substantial influence on connec-
tive tissue remodeling after myocardial infarction or vascu-
lar wall injury.11,12 In many circumstances, these effects
arise through a direct modification of fibroproliferative tis-
Abdominal aortic aneurysms (AAAs) are characterized
by segmental dilatation of the aortic wall and pathologic
remodeling of the extracellular matrix.1 Although elastin
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Purpose: Pathologic remodeling of the extracellular matrix is a critical mechanism in the development and progression
of abdominal aortic aneurysms (AAAs). Although angiotensin-converting enzyme (ACE) inhibitors are known to alter
vascular wall remodeling in other conditions, their effects on AAAs are unknown. In this study we assessed the effect
of ACE inhibitors in a rodent model of aneurysm development.
Methods: Male Wistar rats underwent transient aortic perfusion with porcine pancreatic elastase, followed by treatment
with one of three ACE inhibitors (captopril [CP], lisinopril [LP], or enalapril [EP]), an angiotensin (AT)1 receptor
antagonist (losartan [LOS]), or water alone (9 rats in each group). Blood pressure and aortic diameter (AD) were mea-
sured before elastase perfusion and on day 14, with an AAA defined as an increase in AD (∆AD) of more than 100%.
The structural features of the aortic wall were examined by means of light microscopy.
Results: Aneurysmal dilatation consistently developed within 14 days of elastase perfusion in untreated rats, coinciding
with the development of a transmural inflammatory response and destruction of the elastic media (mean ∆AD, 223%
± 28%). All three ACE inhibitors prevented AAA development (mean ∆AD: CP, 67% ± 4%; LP, 18% ± 12%; and EP,
14% ± 3%; each P < .05 vs controls). ACE inhibitors also attenuated the degradation of medial elastin without dimin-
ishing the inflammatory response. Surprisingly, the aneurysm-suppressing effects of ACE inhibitors were dissociated
from their effects on systemic hemodynamics, and LOS had no significant effect on aneurysm development compared
with untreated controls (mean ∆AD, 186% ± 19%).
Conclusion: Treatment with ACE inhibitors suppresses the development of elastase-induced AAAs in the rat. Although
this is associated with the preservation of medial elastin, the mechanisms underlying these effects appear to be distinct
from hemodynamic alterations alone or events mediated solely by AT1 receptors. Further studies are needed to eluci-
date how ACE inhibitors influence aortic wall matrix remodeling during aneurysmal degeneration. (J Vasc Surg
2001;33:1057-64.)
sue healing rather than hemodynamic changes alone, and
they may involve inhibition of ACE in the vessel wall, as
opposed to the circulating enzyme alone.13-15 ACE
inhibitors prevent the generation of angiotensin-II (Ang-
II), and many of the effects of Ang-II involve activation of
cellular AT1 receptors; thus, specific AT1 receptor antago-
nists have also been developed for clinical application.16,17
Despite the widespread use of ACE inhibitors and AT1
receptor antagonists in patients with cardiovascular disease,
their potential effects on aortic aneurysms are unknown.
In this study we investigated whether treatment with
ACE inhibitors has a favorable influence on the process of
aneurysmal degeneration. To test this, we examined the
effects of three different ACE inhibitors and a selective
AT1 receptor antagonist on the development of elastase-
induced AAAs in the rat. Our results demonstrate that
ACE inhibitors consistently suppress experimental aortic
aneurysms by attenuating aortic wall connective tissue
destruction, but that these effects are distinct from
changes in systemic hemodynamics alone or events medi-
ated solely by AT1 receptors. These findings provide a
basis for further investigations on the molecular mecha-
nisms of aneurysmal degeneration and suggest the poten-
tial usefulness of ACE inhibitors in patients with AAAs.
MATERIALS AND METHODS
Elastase perfusion model of abdominal aortic
aneurysm. Male Wistar rats (350-400 g) underwent tran-
sient perfusion of the abdominal aorta according to a pro-
tocol approved by the Washington University Animal Care
Committee, as described.18-20 In brief, a laparotomy was
performed under sterile conditions, and the abdominal
aorta was exposed from the level of the left renal vein to the
aortic bifurcation. A PE-10 polyethylene catheter (Baxter,
McGraw Park, Ill) was introduced through a femoral arte-
riotomy, and its tip was positioned within the distal abdom-
inal aorta. The preperfusion aortic diameter (AD) was
measured to within 0.05 mm with a binocular surgical
microscope equipped with a scaled grid (Leica, Deerfield,
Ill). The infrarenal aorta was clamped above the level of the
catheter tip, and a silk ligature was secured around the aor-
tic bifurcation to encompass the catheter without occlud-
ing it. The isolated segment of distal abdominal aorta
(approximately 15 mm in length) was then perfused with 2
mL of saline alone or saline containing 50 units of type I
porcine pancreatic elastase (E-1250 purchased before
February 1997, Sigma Chemical, St Louis, Mo).21 Aortic
perfusion was performed in a 2-hour period with a syringe
pump to maintain pressure at 100 mm Hg (Sage
Instruments, Boston, Mass). After perfusion, the aortic
clamp and silk ligatures were removed, the polyethylene
catheter was withdrawn, and the femoral artery was ligated.
The postperfusion AD was measured 5 minutes after
restoration of the aortic blood flow. Animals were allowed
to recover from anesthesia and were maintained in individ-
ual cages with free access to food and water for as long as
14 days. At that time, the abdominal aorta was reexposed
through a laparotomy, and the final AD was remeasured
under physiologic conditions immediately before the rats
were euthanized with intravenous pentobarbital. Measure-
ments of the preperfusion, postperfusion, and final AD
were recorded for each animal. The increase in AD was cal-
culated (∆AD = final AD – preperfusion AD) and expressed
as a percentage change for each animal (∆AD%). An AAA
was defined as a ∆AD% greater than 100.
Control groups. Two control groups were used to
verify the consistency of aneurysm development. The first
group consisted of six rats that underwent aortic perfu-
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Fig 1. Development of elastase-induced abdominal aortic
aneurysms in the rat. AD measurements after transient perfusion
with either saline or elastase are expressed as percent increase
between preperfusion and final AD. Each bar represents mean ±
SEM for six rats. AAAs (horizontal line) consistently developed
within 7 days of elastase perfusion and were uniformly present by
day 14. *P < .05 vs day 0, Student t test.
Fig 2. Effect of ACE inhibitors on the development of elastase-
induced AAAs. Aneurysmal dilatation was assessed 14 days after
elastase perfusion in animals treated with water alone or water
supplemented with 250 mg/L of either captopril (CP), lisinopril
(LP), enalapril (EP), or losartan (LOS). Each bar represents mean
± SEM for six rats, with AAAs (horizontal line). *P < .05, com-
pared with water-treated controls.
sion with saline alone, then were killed on day 14. The
second group consisted of 18 rats that underwent aortic
perfusion with elastase, then were killed on day 2, 7, or
14 (6 rats at each interval). All control animals were pro-
vided with free access to normal drinking water for the
entire period after perfusion.
Experimental (pharmacologic treatment) groups.
There were four experimental groups, each consisting of
nine rats that underwent aortic perfusion with elastase.
Beginning on the day of elastase perfusion, experimental
animals were given drinking water supplemented with 250
mg/L of captopril (CP), lisinopril (LP), enalapril (EP), or
losartan (LOS). A generic form of CP was purchased from
Sigma Chemical, and proprietary forms of LP (Prinivil),
EP (Vasotec), and LOS (Cozaar) were purchased from
Merck (West Point, Pa). The route of administration that
was used resulted in a daily intake of 4 to 6 mg/kg for
each compound tested, a dose consistent with other exper-
imental studies in rats in which these agents have exerted
significant pharmacologic effects.22-25
Hemodynamic measurements. Three rats in each
group were used as a means of determining the effect of
drug treatment on systemic hemodynamics. At the time of
transfemoral cannulation of the abdominal aorta, arterial
blood pressure (BP) and ambient heart rate were mea-
sured directly and recorded on a strip-chart (Gould
Instrument Systems, Valley View, Ohio). Six individual
recordings were made in a 30-minute period of stabiliza-
tion, and the mean (± SE) of these values was used to
establish the pretreatment baseline conditions for each
animal. Hemodynamic measurements were repeated with
the same technique after 14 days of drug treatment (or
water alone).
Histology. After euthanasia, three animals in each
group underwent systemic perfusion with 10% neutral
buffered formalin (120 mm Hg for 10 minutes). The
involved segment of abdominal aorta was excised,
immersed in 10% neutral buffered formalin (4°C
overnight), and processed for routine paraffin embedding.
Aortic tissue cross sections (7 µm) were stained with
Verhoeff-van Gieson stain for elastin and examined under
a BX60 light microscope with a PM-30 automatic pho-
tomicrographic system (Olympus America, Melville, NY).
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Statistical analysis. For each of the control and drug
treatment groups, the mean ± SE of preperfusion AD,
postperfusion AD, final AD, ∆ADmm, and ∆AD% was
determined, along with the percent of animals that had
AAAs. Statistical comparisons between the groups were
made with analysis of variance (ANOVA) with the
Student-Newman-Keuls multiple comparisons test; the 2-
tailed, unpaired Student t test; or χ2 analysis.26 The over-
all percent inhibition of aortic dilatation for each drug was
determined by comparing the mean ∆AD% for each treat-
ment group with that of the elastase perfused, untreated
control group. For analysis of hemodynamic data, the dif-
ferences between pretreatment and posttreatment BP
measurements were compared for each group of rats with
the paired Student t test. Pearson correlation coefficients
were used to determine whether there was any relationship
between the effects of drug treatment on aneurysmal
dilatation and the effects on systolic, diastolic, or mean BP.
RESULTS
AD consistently increased by approximately 30%
immediately after aortic perfusion with either saline or
elastase, but subsequently decreased to normal in animals
perfused with saline alone (Fig 1). In contrast, AD was sta-
ble for as long as 2 days in animals undergoing perfusion
with elastase, followed by a progressive increase. The
mean AD thus reached aneurysmal proportions in most
elastase-perfused animals by day 7 and enlarged further by
day 14, with AAAs developing in all animals by this inter-
val. These findings are consistent with our earlier studies
on the temporal development of elastase-induced AAAs in
the rat.18-20,27
Table I summarizes the effects of drug treatment on
AD measurements after elastase perfusion. Although
aneurysmal dilatation developed in all animals given nor-
mal drinking water by day 14, treatment with ACE
inhibitors resulted in a significant reduction in both final
AD and ∆AD. This inhibitory effect was greatest for EP
and LP, but it was also significant for CP; indeed, no AAAs
were observed in any of the rats treated with ACE
inhibitors (P < .05). These experiments also revealed that
treatment with the AT1 receptor antagonist, LOS, had no
significant effect on either final AD or ∆AD, with all of the
Table I. AD measurements in drug treatment groups
Treatment AD Pre (mm) AD Post (mm) AD Final (mm) ∆AD (mm) No. of AAAs
Water 1.60 ± 0.02 2.78 ± 0.07 5.17 ± 0.44 3.57 ± 0.75 6 of 6
Captopril 1.61 ± 0.03 2.41 ± 0.06 2.96 ± 0.21* 1.34 ± 0.34* 0 of 6†
Lisinopril 2.08 ± 0.03 2.51 ± 0.05 2.47 ± 0.26* 0.39 ± 0.25* 0 of 6†
Enalapril 1.99 ± 0.08 2.45 ± 0.08 2.34 ± 0.15 0.35 ± 0.09* 0 of 6†
Losartan 1.65 ± 0.02 2.45 ± 0.08 4.58 ± 0.57 2.92 ± 0.80 6 of 6
Measurements were obtained immediately before (Pre) and after (Post) elastase perfusion and 14 days later (Final). The increase in AD (∆AD) was deter-
mined for each animal to be the difference between final AD and the preelastase baseline AD. The number of individual animals in which AAAs developed
(∆AD > 100%) was recorded. Animals were treated with the agents indicated beginning on the day of elastase perfusion (250 mg/L in the drinking water).
All data represent the mean ± SEM.
*P < .05 vs water, Student t test.
†P < .05 vs water, χ2 analysis.
LOS-treated animals exhibiting AAAs on day 14. As illus-
trated in Fig 2, similar results were observed for the extent
of aortic dilatation in each of the treatment groups.
Compared with that of untreated controls, the overall
inhibition of aortic dilatation was 70% for CP, 92% for LP,
and 94% for EP.
Fig 3 illustrates the characteristic histopathologic
changes that occurred during the development of elastase-
induced AAAs. Compared with the normal (preperfusion)
aorta, there was little alteration in medial elastin 14 days
after perfusion with saline. In contrast, 14 days after per-
fusion with elastase and treatment with normal drinking
water, aneurysmal dilatation was associated with a chronic
transmural inflammatory response and extensive destruc-
tion of the medial elastic lamellae. This is consistent with
our earlier observations in this model, in which aneurys-
mal dilatation is closely associated with a mononuclear
inflammatory response and widespread degradation of
medial elastin.18-20,27 Most important, we found that ani-
mals undergoing elastase perfusion and treatment with
ACE inhibitors exhibited obvious preservation of aortic
wall elastin. This occurred with each of the three ACE
inhibitors tested, and it did not appear to be associated
with a reduction in the aortic wall inflammatory response.
Changes in systemic BP were measured before and
after 14 days of drug treatment to evaluate whether there
was any correlation between the aneurysm-suppressing
effects of ACE inhibitors and their hemodynamic effects
(Table II). The mean BP in water-treated rats was
unchanged between the two time points, and the SE of
these measurements was less than 5% of the recorded val-
ues. In addition, these BP measurements were similar to
those obtained in other studies with normotensive Wistar
rats by means of either direct catheterization or tail-cuff
plethysmography.28 There were considerable differences
in the hemodynamic effects of the compounds used in
this study at the single dose tested, with LP producing
the greatest effect on mean BP (38% reduction) and EP
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Fig 3. Effect of ACE inhibitors on histology of elastase-induced AAAs. Transverse sections of formalin-fixed aortic tissue were stained
with Verhoeff-van Gieson stain for elastin. a, Normal preperfusion aorta. b, Fourteen days after perfusion with saline, no aneurysmal
dilatation. c, Fourteen days after perfusion with elastase, marked aneurysmal dilatation. d, Fourteen days after perfusion with elastase
and captopril (CP) treatment, no aneurysmal dilatation. Elastase-induced AAAs were associated with chronic inflammation and destruc-
tion of medial elastin (short arrows). Treatment with ACE inhibitors was associated with preservation of elastic lamellae (long arrow; orig-
inal magnification, 100×).
the least (8% reduction). Treatment with LOS was also
associated with no significant hemodynamic changes (2%
increase in mean BP). Fig 4 illustrates the disparity
between the hemodynamic actions of these drugs and
their effects on aneurysm development. Although LP
and EP both resulted in a pronounced suppression of
aortic dilatation, their effects on BP differed widely.
Furthermore, there was no discernible difference
between the hemodynamic effects of EP and LOS, but
the effects of these two agents diverged markedly for
aneurysmal dilatation. We therefore found no significant
relationship between the suppressive effects of ACE
inhibitors on aneurysmal dilatation and their potential
effects on hemodynamic wall stress.
DISCUSSION
The purpose of this study was to begin investigating
the potential effects of ACE inhibitors on the develop-
ment of aortic aneurysms. This is important because AAAs
are a common life-threatening disease for which no phar-
macologic treatment yet exists and because ACE
inhibitors are widely used in the management of cardio-
vascular disorders that often occur in conjunction with
AAAs. Effects of ACE inhibitors on the remodeling of car-
diovascular tissues may also have implications for the
pathophysiologic mechanisms of aneurysm disease. By
using an elastase-induced rodent model, we found that
treatment with each of three different ACE inhibitors
effectively prevented the development of aneurysms in
vivo. Although these ACE inhibitors did not appear to
alter the influx of mononuclear inflammatory cells into the
elastase-injured aortic wall, their inhibitory effects on aor-
tic dilatation were associated with the preservation of aor-
tic medial elastin, a finding consistent with the notion that
matrix degradation is critical in aneurysm development.
The results of this study thereby demonstrate for the first
time that treatment with ACE inhibitors can suppress the
development of experimental AAAs.
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Earlier studies have demonstrated that chronic trans-
mural inflammation and elevated expression of MMPs
make essential contributions to the development of elas-
tase-induced aneurysms in the rat.29,30 The response to
elastase perfusion includes delayed aortic wall infiltration
by mononuclear phagocytes, which is temporally associ-
ated with elastin degradation and elevated local production
of elastolytic MMPs.18,30 Elastase-induced aneurysmal
dilatation is attenuated by treatment with glucocorticoids,
immunosuppressant agents, and leukocyte-depleting mon-
oclonal antibodies, all of which interfere with the chronic
inflammatory response.31,32 Elastase-induced aneurysms
are also suppressed by nonsteroidal anti-inflammatory
drugs, MMP-inhibiting tetracycline derivatives, and other
direct MMP inhibitors; in each case, the effect on aortic
dilatation coincides with structural preservation of aortic
medial elastin without an alteration in the inflammatory
response.18-20,33-35 These experimental observations sug-
gest that anti-inflammatory drugs or pharmacologic sup-
pression of matrix-degrading enzymes might eventually be
useful means of preventing aneurysm expansion in patients
with small, asymptomatic AAAs.8,36-38 The current study
indicates that treatment with ACE inhibitors should also
be considered among the potential pharmacologic strate-
gies for aneurysm disease.
Our findings demonstrated no correlation between
the hemodynamic effects of ACE inhibitors and their sup-
pression of AAAs, leading us to conclude that the
aneurysm-suppressing effects of ACE inhibitors cannot be
explained solely by changes in systemic hemodynamics.
Normotensive adult rats were used in the current study,
and we obtained direct BP measurements with an intra-
arterial catheter under similar experimental conditions at
each time point. The reliability and reproducibility of
these measurements are indicated by the observation that
BP in water-treated rats was unchanged between the two
time points, and that in each case, the SE was less than 5%
of the mean recorded values. The BP measurements
Table II. BP measurements in drug treatment groups
Water Captopril Lisinopril Enalapril Losartan
Systolic BP (mm Hg)
Day 0 118 ± 3 117 ± 2 131 ± 2 133 ± 3 123 ± 2
Day 14 128 ± 4 107 ± 2 88 ± 4 128 ± 5 131 ± 4
∆ (+7.3%) (–8.6%)* (–33.1%) (–4.0%) (+6.1%)
Diastolic BP (mm Hg)
Day 0 91 ± 1 92 ± 1 105 ± 1 104 ± 2 92 ± 1
Day 14 89 ± 2 78 ± 2 62 ± 4 93 ± 3 91 ± 3
∆ (–2.0%) (–15.8%)* (–41.4%)* (–10.6%) (–0.8%)
Mean BP (mm Hg)
Day 0 100 ± 2 100 ± 2 114 ± 1 114 ± 2 103 ± 1
Day 14 102 ± 3 87 ± 2 70 ± 4 105 ± 5 105 ± 3
∆ (+1.7%) (–13.1%)* (–38.2%)* (–8.0%) (+2.0%)
Aortic BP measurements were obtained in a 30-minute period through a transfemoral catheter on day 0. Animals were treated for 14 days with either water
alone or the indicated drugs (250 mg/L in the drinking water), and the BP measurements were repeated. The change in BP (∆) was determined for each
animal to be the difference between the final and the pretreatment baseline. All data represent the mean ± SEM. 
*P < .05 vs water, Student t test.
obtained in control animals also were similar to those in
other studies with normotensive male Wistar rats with
either direct catheterization or tail-cuff plethysmogra-
phy.28 Other studies in which the elastase-induced rat
model was used support the view that a reduction in sys-
temic BP is insufficient to suppress AAAs. For example,
Slaiby et al39 found that beta-adrenergic blockade with
propranolol did not affect aneurysmal dilatation in nor-
motensive rats, although it did suppress the accelerated
aneurysm development observed in rats with spontaneous
hypertension. Because we compared each of the drugs
used in the current study at a single dose, it remains pos-
sible that more pronounced effects on AAAs might have
been observed at doses resulting in more substantial
hemodynamic changes, at least for some of the com-
pounds tested (including LOS). Further studies will there-
fore be needed to examine the dose-specific effects of
these agents on aneurysm development and to examine
how our results might have been altered in the presence of
sustained hypotension. It will also be of interest to exam-
ine the effects of ACE inhibitors and AT1 receptor antag-
onists on elastase-induced AAAs in hypertensive rats.
Because ACE inhibitors act to prevent the conversion
of Ang-I to Ang-II, the results of this study suggest that
Ang-II plays an important role in the pathophysiology of
aneurysmal degeneration. This notion is also supported
by two recent experimental studies in genetically altered
mice. For example, Nishijo et al40 found that transgenic
overexpression of Ang-II is associated with the develop-
ment of aneurysmal aortic lesions in hypertensive animals
placed on a high-salt diet. These lesions had histologic
features of aortic dissection and they were frequently
complicated by rupture, but there was no association
between the occurrence of these lesions and further alter-
ations in the hypertension exhibited by these animals.
More recently, Daugherty et al41 found that sustained
infusion of Ang-II leads to aneurysmal lesions in the ath-
erosclerosis-prone apoE-/- mouse and that this occurs in
the absence of systemic hypertension. The aortic lesions
included chronic inflammation in the outer aortic wall
and breaks in the elastic media, but were not associated
with atherosclerotic plaques, thereby bearing similarity to
the type of aneurysmal degeneration that occurs in the
elastase perfusion model. Because aneurysms were not
observed in apoE-deficient mice in the absence of Ang-II
infusion, the authors concluded that the combination of
hyperlipidemia and Ang-II had accelerated the develop-
ment of aortic wall inflammation. This is consistent with
evidence that Ang-II has a direct effect on monocyte
recruitment and macrophage activation,42-46 supporting
the view that Ang-II might directly contribute to the
development of aneurysmal dilatation.
ACE and Ang-II are recognized as having important
effects on vessel wall remodeling and on the functional
behavior of vascular wall cell types, including smooth mus-
cle cells and mononuclear phagocytes.42-48 Ang-II acts to
stimulate smooth muscle cell proliferation, matrix deposi-
tion, and expression of plasminogen activator inhibitor-1
(PAI-1),49-54 and its effects on target cells occur through
several different receptors. Because in many situations the
effects on fibrotic tissue remodeling appear to be mediated
by the AT1 receptor subtype,55 the effects of ACE
inhibitors can often be reproduced by specific AT1 recep-
tor antagonists. To further investigate the possibility that
ACE inhibitors might have mediated the suppression of
AAAs through a reduction in Ang-II, we examined the
effects of the AT1 receptor antagonist, LOS. This com-
pound had no significant effect on either aortic elastin
degradation or aneurysm development, indicating that the
effect of ACE inhibitors in the elastase-induced rat model
cannot be explained solely by a reduction in AT1 receptor-
mediated events. These observations, however, do not
exclude the possibility that ACE inhibitors might have
suppressed activities mediated by other Ang-II receptor
subtypes,56-60 that they may have influenced local produc-
tion of other biologically active angiotensins (eg, Ang-III
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Fig 4. Comparison of ACE inhibitors, aortic dilatation versus hemodynamic effects. Effects of different agents on elastase-induced aor-
tic dilatation at day 14 are compared with their effects on mean arterial BP, with abdominal aortic aneurysms (AAAs) indicated (hori-
zontal line). There was no significant correlation demonstrated, r = 0.28), indicating that ACE inhibitors suppress aneurysmal
degeneration by a mechanism(s) independent of their hemodynamic effects.
and Ang-IV),61,62 or that they may have exerted their
effects by inhibiting the degradation of vasoactive
kinins.12 Further investigations will be required to deter-
mine whether these additional pharmacologic effects of
ACE inhibitors are responsible for modulating connective
tissue destruction in the aneurysmal aorta.
Another mechanism that may explain the effects of
ACE inhibitors in this study resides in the capacity of these
compounds to directly block the activity of MMPs. Like
converting enzyme, all members of the MMP family are
zinc-dependent metalloenzymes. Recent studies indicate
that the proteinase-inhibiting effects of at least some ACE
inhibitors can also extend to MMPs and that these effects
can be sufficient to inhibit MMP-mediated processes such
as tumor growth and metastasis, angiogenesis, and exper-
imental heart failure.63-66 It is therefore quite possible that
ACE inhibitors might have acted to inhibit elastin-degrad-
ing members of the MMP family that play a crucial role in
aneurysmal degeneration, such as gelatinase B (MMP-
9).67 This hypothesis is supported by our observation that
aortic elastin was well preserved in elastase-perfused ani-
mals treated with ACE inhibitors, despite the presence of
mononuclear inflammation. Further studies will be
required, however, to elucidate whether the suppression of
aneurysmal dilatation by ACE inhibitors is caused by a
direct pharmacologic inhibition of elastin-degrading
MMP activities within the elastase-injured aortic wall. The
recent development of a murine model of elastase-induced
AAAs may facilitate efforts to address this question with
more specificity, with genetically altered mice.67
In conclusion, this study demonstrated for the first time
that ACE inhibitors have an important influence on experi-
mental aneurysmal degeneration. It is not yet clear how these
compounds achieve this effect, and additional investigations
will be needed to elucidate the molecular, cellular, and phys-
iologic mechanisms in more detail. It is also not known
whether these experimental observations can be extended to
aneurysmal degeneration as it occurs in humans, because
there is no information yet available on how ACE inhibitors
influence aneurysm expansion in patients with small asymp-
tomatic AAAs. It will, therefore, be of interest to examine
these questions in future investigations.
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